Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.

Abstract: A combination of THC, CBD and Cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as Shea butter cream to relieve pain. The THC and CBD mixture is extracted from a Cannabis indica dominant strain using high pressure and carbon dioxide (CO2) as a solvent and comprises: Tetrahydrocannabinol “THC” (9-Tetrahydrocannabinol (delta-9 THC), 8-Tetrahydrocannabinol (Delta-8 THC) and 9-THC Acid), Cannabidiol “CBD”, Cannabinol “CBN”, Cannabichromene (“CBC), Cannabigerol (“CBG”), terpenoids and flavonoids. The Shea butter is an extract from the Shea nut from the Shea tree (Vitellaria paradoxa). The weight of THC, CBD and Cobalamin, excluding other ingredients in the Indica extract, is in the range of about 1.0% to 5% of the total weight of the Shea butter. The cream is applied to joints for indications such as Psoriatic Arthritis and Scleroderma.

Abstract: The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

Abstract: A cellulose ester, wherein, in a structural formula of the following general formula (I), a degree of substitution where X is an acyl group is from 2.91 to 3.0; the acyl group includes benzoyl group (A) optionally having a substituent, and benzoyl group (B) optionally having a substituent different from that of benzoyl group (A); and when the degree of substitution is 3.0, a degree of substitution of benzoyl group (A) is from 1.5 to 2.9, and a degree of substitution of benzoyl group (B) is from 0.1 to 1.5, wherein all or some of X represents an acyl group; when some of X represents an acyl group, the remainder represents a group selected from a hydrogen atom and an alkyl group; and n represents an integer of from 20 to 20,000.

Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.

Abstract: Provided are methods and compositions for treating AML in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and an AML induction and consolidation therapy.

Abstract: The present invention relates to a composition of multivitamin vitamin B-C, particularly a composition of vitamin B-C for stimulating gastrointestinal (GI) system motility. The composition is suitable for preventing and/or treating conditions or diseases associated with insufficient GI motility.

Abstract: The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.

Abstract: The present specification relates to a novel compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the compound being capable of being widely used in post fermented tea-related industries and various fields in which the compound may be used.

Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Abstract: The present invention provides methods for treating or suppressing tumor metastasis at a site distinct from the bladder in an individual having a urothelial carcinoma of lower tract, comprising locally delivering to the bladder an effective amount of a chemotherapeutic agent (such as gemcitabine), wherein the chemotherapeutic agent is delivered continuously to the bladder for a sustained period of time (such as at least 24 hours).

Abstract: The agent for inhibiting inflammation promoted by GM3 of the present invention comprises a substance that inhibits inflammation promoted by GM3 as an active ingredient. The substance which inhibits inflammation promoted by GM3 is preferably a ganglioside having 2 or more of sialic acids. The ganglioside having 2 or more of sialic acids is at least one kind of ganglioside selected from the group consisting of GD1c, GD1a, GT1a, GD3, GD2, GD1b, GT1b, GQ1b, GT3, GT2, GT1c, GQ1c, and GP1c. Further, the substance which inhibits inflammation promoted by GM3 has a structure represented by the following formula (1): [In the formula (1), R1 represents a glycan constituting ganglioside GM3, R2—C(?O)— represents a fatty acid residue having 18 or less of carbon atoms, or an unsaturated fatty acid residue having 20 or more of carbon atoms.

Abstract: Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).

Abstract: Compositions are provided that have at least two of three active ingredients. The active ingredients maybe a salt having a cation N?C8-C16 alkanoyl-L di-basic amino acid —C1-C4 alkyl ester, a glycerol monoester of a fatty acid and a sugar ester of a fatty acid. The compositions are useful in methods of killing or inhibiting planktonic bacteria or fungi and bacteria or fungi embedded in a biofilm and prevention of biofilm formation on surfaces. The composition may further comprise a hydrogel and a benefit agent such as an antibiotic that can be solubilized by the hydrogel and supplied to the biofilm matrix by the active ingredients of the composition. Devices such as chronic wound coverings coated with the composition are also provided. Methods of preserving products with the composition are also provided.

Abstract: Provided is a polymer material containing at least one kind of a cellulose derivative having (a) an organosilyl group (the organosilyl group having a first aliphatic group, an unsaturated aliphatic group, or an aromatic group), and (b) an acyl group or a second aliphatic group.

Abstract: The present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof. Specifically, the present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 represented by formula (1), i.e., (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof.

Abstract: A dendritic cell immune receptor activator, comprising a compound having a sugar chain as an active ingredient, the sugar chain having a basic structure represented by the following formula: wherein, in the formula, a sialic acid does not exist at two non-reducing terminals, and each of x and y independently represents 3 or 4.

Abstract: The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and the use of the solid form in the treatment of a disease involving abnormal cell proliferation or a viral infectious disease.

Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

Abstract: The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.